Healthinvest Partners Ab 13F annual report

Healthinvest Partners Ab is an investment fund managing more than $164 billion ran by Margareta Spjut. There are currently 38 companies in Mrs. Spjut’s portfolio. The largest investments include Eli Lilly Co and UFP Technologies, together worth $40.7 billion.

Limited to 30 biggest holdings

$164 billion Assets Under Management (AUM)

As of 7th August 2024, Healthinvest Partners Ab’s top holding is 27,144 shares of Eli Lilly Co currently worth over $24.6 billion and making up 15.0% of the portfolio value. In addition, the fund holds 31,680 shares of UFP Technologies worth $16.1 billion, whose value grew 67.4% in the past six months. The third-largest holding is Merck Co Inc worth $14 billion and the next is Thermo Fisher Scientific worth $10.8 billion, with 19,458 shares owned.

Currently, Healthinvest Partners Ab's portfolio is worth at least $164 billion. The total portfolio value may be much higher due to cash assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.

Careers at Healthinvest Partners Ab

The Healthinvest Partners Ab office and employees reside in Stockholm, Sweden. According to the last 13-F report filed with the SEC, Margareta Spjut serves as the Operations Manager at Healthinvest Partners Ab.

Recent trades

In the most recent 13F filing, Healthinvest Partners Ab revealed that it had opened a new position in UFP Technologies and bought 9,800 shares worth $2.59 billion. This means they effectively own approximately 0.1% of the company. UFP Technologies makes up 13.8% of the fund's Materials sector allocation and has grown its share price by 83.2% in the past year.

The investment fund also strengthened its position in Eli Lilly Co by buying 6,366 additional shares. This makes their stake in Eli Lilly Co total 27,144 shares worth $24.6 billion.

On the other hand, there are companies that Healthinvest Partners Ab is getting rid of from its portfolio. Healthinvest Partners Ab closed its position in Elevance Health Inc on 14th August 2024. It sold the previously owned 7,400 shares for $3.84 billion. Margareta Spjut also disclosed a decreased stake in Merck Co Inc by 0.2%. This leaves the value of the investment at $14 billion and 112,734 shares.

One of the smallest hedge funds

The two most similar investment funds to Healthinvest Partners Ab are Windle Wealth and Sciencast Management L.P.. They manage $164 billion and $164 billion respectively.

Margareta Spjut investment strategy

Healthinvest Partners Ab’s portfolio is diversified across 4 sectors. Currently, their heaviest sector is Health Care — making up 56.3% of the total portfolio value. The fund focuses on investments in the United States as 68.4% of the portfolio companies are based in the United States.

The majority of the companies in the fund’s portfolio are large-cap stocks. Stocks with a size of more than $10 billion in market cap make up 34% of the total holdings value. On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio. The average market cap of the portfolio companies is close to $40 billion.

The complete list of Healthinvest Partners Ab trades based on 13F SEC filings

These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.

Security	Shares Owned	Value	Allocation
Eli Lilly Co	30.64% 27,144	$24,575,634,000	14.98%
UFP Technologies Inc.	37.49% 31,680	$16,133,356,000	9.84%
Merck Co Inc	15.71% 112,734	$13,956,469,000	8.51%
Thermo Fisher Scientific Inc.	28.13% 19,458	$10,760,274,000	6.56%
AMGEN Inc.	46.04% 27,589	$8,620,183,000	5.26%
Boston Scientific Corp.	37.67% 106,557	$8,205,954,000	5.00%
Regeneron Pharmaceuticals, Inc.	27.81% 6,893	$7,244,749,000	4.42%
Vertex Pharmaceuticals, Inc.	33.64% 15,095	$7,075,328,000	4.31%
Cencora Inc.	48.44% 30,320	$6,831,096,000	4.17%
Stryker Corp.	31.87% 19,983	$6,799,215,000	4.15%
Abbvie Inc	21.37% 35,618	$6,109,199,000	3.73%
Dexcom Inc	31.20% 34,483	$3,909,682,000	2.38%
Elevance Health Inc	Closed 7,400	$3,837,196,000
Gilead Sciences, Inc.	Closed 52,000	$3,809,000,000
Edwards Lifesciences Corp	47.35% 36,505	$3,371,966,000	2.06%
Neurocrine Biosciences, Inc.	45.65% 23,630	$3,253,142,000	1.98%
Fusion Pharmaceuticals Inc.	Closed 138,836	$2,959,984,000
IQVIA Holdings Inc	39.03% 13,984	$2,956,776,000	1.80%
Molina Healthcare Inc	20.83% 9,500	$2,824,350,000	1.72%
Cardinal Health, Inc.	No change 27,500	$2,703,800,000	1.65%
UFP Technologies Inc.	Opened 9,800	$2,585,926,000	1.58%
Mirum Pharmaceuticals Inc	38.86% 75,200	$2,571,088,000	1.57%
Intra-Cellular Therapies Inc	5.81% 35,841	$2,454,750,000	1.50%
Ionis Pharmaceuticals Inc	36.21% 40,691	$1,939,333,000	1.18%
Merus N.V	26.77% 30,837	$1,824,625,000	1.11%
Corbus Pharmaceuticals Hldgs	2.89% 39,100	$1,769,275,000	1.08%
Alkermes plc	Opened 68,800	$1,658,080,000	1.01%
Shockwave Med Inc	Closed 4,751	$1,547,068,000
Option Care Health, Inc.	59.07% 54,395	$1,506,741,000	0.92%
Amicus Therapeutics Inc	41.26% 148,207	$1,470,213,000	0.90%
Newamsterdam Pharma Company	238.46% 75,794	$1,456,002,000	0.89%
Krystal Biotech Inc	15.10% 7,624	$1,400,071,000	0.85%
BridgeBio Pharma Inc	41.20% 53,432	$1,353,432,000	0.83%
Arcellx Inc	28.58% 22,496	$1,241,554,000	0.76%
Exact Sciences Corp.	Closed 16,120	$1,113,247,000
Harmony Biosciences Hldgs In	79.47% 34,900	$1,052,933,000	0.64%
Inspire Med Sys Inc	Closed 4,782	$1,027,126,000
Cytokinetics Inc	Closed 14,000	$981,540,000
Madrigal Pharmaceuticals Inc	Closed 3,539	$945,055,000
Immunocore Hldgs Plc	41.86% 23,778	$805,836,000	0.49%
Autolus Therapeutics plc	134.72% 226,145	$786,984,000	0.48%
Morphic Hldg Inc	35.09% 20,199	$688,179,000	0.42%
Pharvaris N V	Opened 34,328	$645,366,000	0.39%
Akero Therapeutics Inc	Closed 24,432	$617,152,000
Macrogenics Inc	190.85% 143,407	$609,479,000	0.37%
Cabaletta Bio Inc	17.05% 64,321	$481,121,000	0.29%
Mersana Therapeutics Inc	84.90% 184,900	$371,649,000	0.23%
No transactions found
Showing first 500 out of 47 holdings